NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) — Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology firm targeted on growing revolutionary therapies for neurodegenerative ailments and selling wholesome longevity, is proud to announce that Dr. Robert Langer, co-founder of Moderna (NASDAQ:), has joined its Scientific Advisory Board. Along with lending his world-class scientific experience to information the corporate’s strategic path, this additionally alerts Dr. Langer’s robust perception within the firm’s mission and potential.
Dr. Langer is a world-renowned scientist, entrepreneur, and biotechnology pioneer. His groundbreaking work in drug supply techniques and tissue engineering has earned him quite a few awards and recognition, together with the celebrated Nationwide Medal of Science and the Charles Stark Draper Prize. As a co-founder of Moderna, Dr. Langer performed a pivotal position in revolutionizing the biotech business with the event of mRNA-based therapeutics, together with the COVID-19 vaccine. He’s a Professor on the Massachusetts Institute of Expertise (MIT) and a college member of the Harvard“MIT Program in Well being Sciences and Expertise.
Klotho Neurosciences is engaged on the event of novel therapies geared toward addressing main unmet medical wants in neurodegenerative issues, together with ALS, Alzheimer’s and Parkinson’s illness. The corporate’s platform leverages groundbreaking analysis surrounding the Klotho protein, a strong anti-aging issue that has proven vital neuroprotective potential in preclinical fashions. Patents masking the corporate’s secreted type of Klotho, s-KL, have been issued within the USA, Europe, Hong Kong and China.
We’re thrilled to welcome Dr. Langer to our Scientific Advisory Board, commented Dr. Joseph Sinkule, the Chairman and CEO of Klotho Neurosciences. His huge expertise in translational medication, biotechnology, and therapeutic innovation will probably be invaluable as we advance our pipeline and discover new approaches to treating devastating neurodegenerative ailments. I’d additionally like to notice that I used to be privileged to have labored with Bob Langer some years in the past once I co-authored a scientific paper with him.
Dr. Langer expressing his enthusiasm for becoming a member of Klotho Neurosciences commented, I’m excited to collaborate with the workforce at Klotho Neurosciences as they discover the therapeutic potential of the Klotho protein in combating neurodegenerative circumstances. The corporate is engaged on one thing extremely promising, and I am desperate to assist their efforts.
As a member of the Scientific Advisory Board, Dr. Langer will present steering on the scientific and scientific improvement of the corporate’s product candidates. Klotho Neurosciences is positioning itself on the forefront of the biotech sector’s efforts to deal with one of the vital urgent challenges of contemporary medication, which is the therapy of neurodegenerative ailments. Dr. Langer’s involvement represents a big milestone for the corporate because it strikes ahead in its mission to develop life-changing therapies for sufferers worldwide primarily based on its patented s-KL know-how platform.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO), a biopharmaceutical firm specializing within the improvement of patented, novel disease-modifying applied sciences concentrating on the mind and central nervous system (CNS) which are seen as key developments in treating neurodegenerative and age-related issues. The Firm obtained unique worldwide rights to platform applied sciences and knowhow to develop leading edge protein, gene and cell therapies to deal with age-related pathologies reminiscent of ALS, Alzheimer’s and Parkinson’s Illness, a number of sclerosis and uncommon neurodegenerative ailments. The corporate’s present portfolio consists of its proprietary gene remedy program utilizing DNA and RNA as therapeutics and diagnostics. Different property embody clinical-stage packages involving antibody biologics concentrating on most cancers and autoimmune ailments, and drug supply through a needle-free dry powder jet autoinjector referred to as Nanoject. The corporate is managed by a workforce of people and advisors who’re extremely skilled in biopharmaceutical product improvement and commercialization.
For extra data, contact:
Eric Boyd
Investor Relations
E mail: [email protected]
Web site: www.klothoneuro.com
Ahead-Wanting Statements:
This press launch comprises forward-looking statements. These statements are made beneath the secure harbor provisions of the U.S. Non-public Securities Litigation Reform Act of 1995. These forward-looking statements typically are recognized by the phrases imagine, challenge, count on, anticipate, estimate, intend, technique, future, alternative, plan, could, ought to, will, would, will probably be, will proceed, will doubtless end result, and comparable expressions. With out limiting the generality of the foregoing, the forward-looking statements on this press launch embody descriptions of the Firm’s future industrial operations. Ahead-looking statements are predictions, projections and different statements about future occasions which are primarily based on present expectations and assumptions and, because of this, are topic to dangers and uncertainties. Many components might trigger precise future occasions to vary materially from the forward-looking statements on this press launch, such because the Firm’s lack of ability to implement its enterprise plans, establish and understand extra alternatives, or meet or exceed its monetary projections and adjustments within the regulatory or aggressive setting through which the Firm operates. You must rigorously think about the foregoing components and the opposite dangers and uncertainties described within the paperwork filed or to be filed by the Firm with the U.S. Securities and Change Fee (the SEC) infrequently, which might trigger precise occasions and outcomes to vary materially from these contained within the forward-looking statements. Copies of those paperwork can be found on the SEC’s web site, www.sec.gov. All data supplied herein is as of the date of this press launch, and the Firm undertakes no obligation to replace any forward-looking assertion, besides as required beneath relevant legislation.
Supply: Klotho Neurosciences, Inc.
